Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3635996 | 0.94 | GRM5 (0.46) | GRM5S1PR1PDE10AALDH1A1SMN1; SMN2 | |
| SCHEMBL3635770 | 0.91 | MEN1 (0.46) | GRM5PDE10AALDH1A1SMN1; SMN2 | |
| SCHEMBL3635686 | 0.90 | GRM5 (0.58) | GRM5PDE10AALDH1A1SMN1; SMN2 | |
| SCHEMBL3629201 | 0.87 | GRM5 (0.60) | GRM5S1PR1PDE10AMAPK10 | |
| SCHEMBL3636827 | 0.82 | ALDH1A1 (0.48) | GRM5S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3637528 | 0.81 | GRM5 (0.60) | GRM5PDE10AALDH1A1 | |
| SCHEMBL3635570 | 0.79 | GRM5 (0.49) | GRM5S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3630176 | 0.78 | GRM5 (0.57) | GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL3636829 | 0.77 | GRM5 (0.75) | GRM5PDE10AMAPK10ALDH1A1 | |
| SCHEMBL3633417 | 0.76 | GRM5 (0.60) | GRM5RIPK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | GRM5 4545/4885S1PR1 3425/4885RIPK2 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.